SOST and plasma cell myeloma: For example, knockout of sclerostin expression in osteocytes or pharmaceutical inhibition of sclerostin can reduce bone lesions in myeloma mouse models9, indicating that the interaction between tumor cells and osteocytes is an essential pathway in the genesis of lytic lesions seen in myeloma patients.